Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release.
Omega Funds and TCGX led the financing round. Contributors included Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc. and Digitalis Ventures. The funding will support the ongoing phase 2b/3 trial investigating AVD-104, as well as the planned pivotal phase 3 clinical trial.
As Healio previously reported, AVD-104